Keyphrases
SFRP1
35%
Pancreatic Adenocarcinoma
34%
Pancreatic Ductal Adenocarcinoma
33%
New-onset Diabetes
32%
Promoter Methylation
32%
Pancreatic Cancer
29%
Cancer-related
22%
Blood Biomarkers
21%
DNA Promoter Hypermethylation
21%
Diabetes
20%
Biochemical Parameters
18%
Gemcitabine
17%
Literature Update
16%
Eosinophilic Esophagitis
16%
Population-based Study
16%
DNA Hypermethylation
16%
Prognostic Marker
16%
Machine Learning Approach
16%
Clinical Target Volume
16%
Blood-based Marker
16%
National Cohort Study
16%
Pancreatic Cancer Risk
16%
External Validation Study
16%
Diagnostic Delay
16%
Cell-free DNA (cfDNA)
16%
Type 2 Diabetes Mellitus (T2DM)
14%
Cox Regression
10%
Food Bolus Obstruction
9%
Receiver Operating Characteristic Curve
8%
Geometric Margin
8%
Gross Tumor Volume
8%
Diagnostic Prediction Model
8%
Radiotherapy Plan
8%
Triglyceride Level
7%
Plasma Triglycerides
7%
Diabetes Diagnosis
7%
Hemoglobin A1c (HbA1c)
7%
Bisulfite Treatment
7%
Log-rank Test
7%
Promoter Region
7%
Median Overall Survival
7%
Cumulative Incidence
6%
Treatment Response
6%
Population-based
5%
Validation Studies
5%
Biochemical Variables
5%
Tumor
5%
BNC1
5%
Validation Cohort
5%
Hypermethylation
5%
Medicine and Dentistry
Pancreas Adenocarcinoma
70%
Promoter Region
64%
Cell-Free DNA
43%
Pancreas Cancer
40%
Biological Marker
35%
Secreted Frizzled-Related Protein 1
27%
Neoplasm
23%
Gemcitabine
18%
Diabetes
16%
Radiation Therapy
16%
Cohort Analysis
16%
Diagnostic Delay
16%
Eosinophilic Esophagitis
16%
Irreversible Electroporation
16%
Diseases
12%
Malignant Neoplasm
10%
Overall Survival
10%
Methylation
10%
Pancreatic Ductal Adenocarcinoma
10%
Bisulfite
10%
Obstruction
9%
Diagnosis
8%
Proportional Hazards Model
8%
Anatomy
8%
Oropharynx
8%
DNA Template
8%
Squamous Cell Carcinoma
8%
Head and Neck Cancer
8%
Cancer Radiotherapy
8%
Treatment Response
6%
Maturity Onset Diabetes of the Young
5%
Cancer Staging
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
100%
Pancreas Cancer
56%
Biological Marker
51%
Secreted Frizzled Related Protein 1
43%
Gemcitabine
24%
Disease
22%
Overall Survival
21%
Chemotherapy
16%
Non Insulin Dependent Diabetes Mellitus
16%
Cohort Study
16%
Bisulfite
13%
Triacylglycerol
10%
Hemoglobin A1c
10%
Progression Free Survival
8%
Neoplasm
8%
Survival Time
8%
Malignant Neoplasm
5%
Cancer Staging
5%